

Published in final edited form as:

J Med Chem. 2012 April 26; 55(8): 3867–3877. doi:10.1021/jm300070h.

Searching for New Chemotherapies for Tropical Diseases: Ruthenium-Clotrimazole Complexes Display High *in vitro* Activity Against *Leishmania major* and *Trypanosoma cruzi* and Low Toxicity Toward Normal Mammalian Cells

 Alberto Martínez[†], Teresia Carreon[‡], Eva Iniguez[‡], Atilio Anzellotti[§], Antonio Sánchez[†], Marina Tyan[†], Aaron Sattler[¶], Linda Herrera[‡], Rosa A. Maldonado^{‡,*}, and Roberto A. Sánchez-Delgado^{†,*}
[†]Chemistry Department, Brooklyn College and The Graduate Center, The City University of New York, Brooklyn, NY 11210, USA.

[‡]Border Biomedical Research Center, Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA

[§]Chemistry Center, Instituto Venezolano de Investigaciones Científicas, IVIC, Caracas, 10203A Venezuela

[¶]Chemistry Department, Columbia University, New York, NY 10027, USA

Abstract

Eight new ruthenium complexes of clotrimazole (CTZ) with high antiparasitic activity have been synthesized, *cis, fac*-[Ru^{II}Cl₂(DMSO)₃(CTZ)] (**1**), *cis, cis, trans*-[Ru^{II}Cl₂(DMSO)₂(CTZ)₂] (**2**), Na[Ru^{III}Cl₄(DMSO)(CTZ)] (**3**) and Na[*trans*-Ru^{III}Cl₄(CTZ)₂] (**4**), [Ru^{II}(η^6 -*p*-cymene)Cl₂(CTZ)] (**5**), [Ru^{II}(η^6 -*p*-cymene)(bipy)(CTZ)][BF₄]₂ (**6**), [Ru^{II}(η^6 -*p*-cymene)(en)(CTZ)][BF₄]₂ (**7**) and [Ru^{II}(η^6 -*p*-cymene)(acac)(CTZ)][BF₄] (**8**) (bipy = bipyridine; en = ethylenediamine; acac = acetylacetonate). The crystal structures of compounds **4–8** are described. Complexes **1–8** are active against promastigotes of *Leishmania major* and epimastigotes of *Trypanosoma cruzi*. Most notably complex **5** increases the activity of CTZ by factors of 110 and 58 against *L. major* and *T. cruzi*, with no appreciable toxicity to human osteoblasts, resulting in nanomolar and low micromolar lethal doses and therapeutic indexes of 500 and 75, respectively. In a high-content imaging assay on *L. major* infected intraperitoneal mice macrophages, complex **5** showed significant inhibition on the proliferation of intracellular amastigotes (IC₇₀ = 29 nM), while complex **8** displayed some effect at a higher concentration (IC₄₀ = 1 μ M).

INTRODUCTION

Parasitic trypanosomatids are the origin of human ailments such as leishmaniasis and Chagas' disease, caused by the *Leishmania* genus and *Trypanosoma cruzi* (*T. cruzi*), respectively. Leishmaniasis is encountered in tropical and subtropical regions of the world and transmitted by certain species of the sand fly (subfamily *Phlebotominae*). Over 20 species and subspecies of *Leishmania* infect humans, causing three varieties of the disease: visceral (VL), cutaneous (CL) and mucocutaneous leishmaniasis (MCL). About 350 million people are at risk in 88 countries; an estimated 12 million people are currently infected and

*Corresponding Author: For R.A. S.-D.: Tel. (718) 951 5000 ext. 2827; RSdelgado@brooklyn.cuny.edu For R. A. M.: Tel. (915) 747-6891; ramaldonado@utep.edu.

around 2 million new infections occur each year, with a third of the global cases being attributable to cutaneous leishmaniasis.¹ The American trypanosome, on the other hand, causes Chagas' disease, which afflicts up to 20 million people with different forms of the pathology in Central and South America. About 5 million are expected to develop severe cardiomyopathy and/or digestive disorders and up to 50,000 people die annually from these complications.² The human infection begins when the metacyclic trypomastigote form of the parasite, present in the *Triatominae* insect vector's feces, invades the host blood through the insect bite wound or nearby mucosa.^{2c} Other major routes of transmission are blood transfusion and organ transplant from infected donors, as well as congenital transmission, which is making Chagas' disease emerge as a serious problem in blood and tissue banks in the U.S., Canada and Europe, due to immigration from endemic countries.³

Most of the available treatments for both diseases are 20 or more years old and they are characterized by high toxicity and limited efficacy:^{4,5} Antimonials (meglumine or antimoniate), amphotericin B or pentamidine for leishmaniasis, and azole or nitro derivatives (benznidazole or nifurtimox) in the case of Chagas' disease. In addition, the vast majority of people afflicted by such diseases do not have the resources to cover the cost of full therapies and therefore pharmaceutical companies find little incentives to develop new drugs. To make matters worse, the emergence of resistant strains to current treatments^{6,7} clearly states the urgent need for new and effective drugs to treat trypanosomatid infections.

Azole-type molecules have been shown to effectively inhibit the growth of trypanosomes thanks to their ability to act as sterol biosynthesis inhibitors (SBIs), which block the proliferation of parasites by inhibiting the cytochrome P-450 dependent C-14- α -demethylation of lanosterol to ergosterol;^{4, 8} some of them, *e.g.* posaconazole and ravuconazole, are expected to enter clinical trials in the short term. Clotrimazole (CTZ) and ketoconazole (KTZ), well known as antifungal agents, also display some anti-*T. cruzi* activity. The sterol biosynthetic pathways of *Trypanosoma* and *Leishmania* are similar to those of pathogenic fungi and therefore their growth is susceptible to sterol biosynthesis inhibitors (SBIs), providing the rationale for the success of these compounds as potent new antiparasitic agents.⁹

An attractive concept that some of us have proposed is the metal-drug synergism, achieved through the combination of a molecule of known biological activity with a metal-containing fragment;¹⁰ such combinations can translate into an enhanced activity of the parental drug, together with a decrease of its toxicity. In addition, the use of metal-based drugs allows the design of chemical entities capable of reaching a variety of specific targets.^{11,12,13,14} In early work we reported metal complexes of CTZ and KTZ with Ru, Rh, Pt, Au and Cu, some of which displayed high activity against *T. cruzi*.¹⁵ The most efficacious compound was RuCl₂(CTZ)₂, which produced a 10-fold increase in activity when compared to free CTZ, accompanied by a notable 10-fold decrease in toxicity against normal mammalian (Vero) cells. A synergistic mechanism of action, involving the liberation of CTZ at the site of action to exert its regular SBI function, coupled with a covalent interaction of the remaining metal-containing fragment to the parasite's DNA to produce nuclear damage, is responsible for the behavior of RuCl₂(CTZ)₂.^{15b} Nevertheless, the low solubility of these compounds in aqueous media translated into poor activities *in vivo*. We also extended the success of the metal-drug synergism to the case of malaria, through a number of metal-chloroquine complexes that are able to overcome resistance to chloroquine in a variety of strains of *Plasmodium falciparum*.^{10, 16}

Using a similar approach, other potential metal-based drugs for Chagas' disease have been described; parasitic cysteine proteases like cruzain and cathepsin B,¹² as well as trypanothione reductase¹³ have been mentioned as possible additional targets for metal-

based antiparasitic drugs. Pd, Pt, and Ru complexes with bioactive nitrofuranyl-containing thiosemicarbazone or pentamidine ligands displayed higher *in vitro* activity than the corresponding ligands or the first line treatment nifurtimox against *T. cruzi* and *T. brucei*.¹⁷ These complexes may act through multiple-target mechanisms probably involving free radicals and/or binding to cruzipain or trypanothione reductase, but not to DNA. Other recently reported metal complexes with anti *T. cruzi* activity include Pt and Pd derivatives of pyridine-2-thiol-N-oxide,¹⁸ a vanadyl complex and a series of Ru nitrothiosemicarbazones containing DNA intercalating ligands,¹⁹ Ru-aryl-4-oxothiazolylhydrazones,²⁰ Pt- and Pd-dithiocarbazates,²¹ Mn-, Co-, Ni- and Cu-risedronates,²² Co and Cu complexes with the triazole ligand 5-methyl-1,2,4- triazolo[1,5-a] pyrimidin-7(4H)-one (HmtpO),²³ and fluoroquinolones coordinated to Mn, Co and Cu.²⁴

In contrast, the search for new more effective and less toxic metal-based therapies for leishmaniasis has received much less attention. Complexes of Rh, Ir or Cu with pentamidine or dppz (dipyrido[3,2-a:2',3'-c]phenazine), and of Pt with terpyridine and other DNA-intercalating ligands,^{10,11,25} have shown interesting activity. Silver polypyridyl derivatives targeting DNA also showed leishmanicidal effects²⁶ and Ag nanoparticles encapsulated in ferritin molecules produced an antiproliferative effect on *Leishmania infantum* by inhibiting trypanothione reductase.²⁷ Cu and Zn derivatives of N-quinolin-8-yl-arylsulfonamides also displayed activity against *L. brasiliensis* and *L. chagasi*.²⁸ Clearly, the discovery of new metal-based drugs for the chemotherapy of leishmaniasis is highly desirable.

In this paper we report the synthesis of a new series of compounds that combine CTZ with ruthenium, along with their activity against *Leishmania major* (*L. major*) and *Trypanosoma cruzi*, and the evaluation of their toxicity against normal human osteoblasts. Ruthenium is an attractive alternative for medicinal applications, due to the low toxicity displayed by compounds of this metal, as a result of the ability of Ru to mimic the binding of iron to biomolecules such as transferrin and albumin.¹⁴ Two molecular designs were envisaged, aiming for a dual target mechanism (SBI action plus selective DNA binding): (i) Octahedral Ru^{II} and Ru^{III} coordination complexes [Ru^{II}Cl₂(DMSO)₃(CTZ)] (**1**), [Ru^{II}Cl₂(DMSO)₂(CTZ)₂] (**2**), Na[Ru^{III}Cl₄(DMSO)(CTZ)] (**3**) and Na[Ru^{III}Cl₄(CTZ)₂] (**4**); and (ii) Organometallic “piano-stool” arene-Ru^{II}-CTZ compounds [Ru^{II}(η^6 -*p*-cymene)Cl₂(CTZ)] (**5**), [Ru^{II}(η^6 -*p*-cymene)(bipy)(CTZ)][BF₄]₂ (**6**), [Ru^{II}(η^6 -*p*-cymene)(en)(CTZ)][BF₄]₂ (**7**) and [Ru^{II}(η^6 -*p*-cymene)(acac)(CTZ)][BF₄] (**8**) (bipy = bipyridine; en = ethylenediamine; acac = acetylacetonate). The ancillary ligands provide the desired stability and modulate the physicochemical properties of the drugs in order to optimize the biological properties.

RESULTS AND DISCUSSION

Chemistry

CTZ is a classic imidazole ligand with a single coordination site (N1) capable of binding a metal atom (Figure 1). The new Ru^{II} and Ru^{III} octahedral complexes **1-4** were prepared as depicted in Scheme 1. *cis*-[Ru^{II}Cl₂(DMSO)₄] reacts smoothly with 1 or 2 eq. of CTZ in methanol to yield the neutral complexes [Ru^{II}Cl₂(DMSO)₃(CTZ)] (**1**) and [Ru^{II}Cl₂(DMSO)₂(CTZ)₂] (**2**), respectively, as air-stable yellow powders. The *cis, fac*-geometry for **1** and *cis, cis, trans*- for **2** were confirmed by NMR and FT-IR spectroscopies: The ¹H NMR spectrum of **1** shows signals typical of N-coordinated CTZ, *i.e.* H2, H4 and H5 shifted 1.04, 0.76 and 0.07 ppm, with respect to the free ligand.¹⁵ The presence of three singlets in the DMSO region of the ¹H NMR, each one integrating for one DMSO molecule, indicates that CTZ has replaced one DMSO molecule in *cis*-[Ru^{II}Cl₂(DMSO)₄], most likely the O-bonded one (Scheme 1, a).²⁹ This is confirmed by elemental analysis and by the presence of IR bands assigned to ν (Ru-S) at 421 cm⁻¹ and ν (S-O) at 1091 cm⁻¹, typical of

S-coordinated DMSO, and the absence of $\nu(\text{Ru-O})$.²⁹ Other known reactions of *cis*- $[\text{Ru}^{\text{II}}\text{Cl}_2(\text{DMSO})_4]$ with imidazoles³⁰ and the extreme conditions required for a potential *cis*/*trans* isomerization³¹ allow us to assign the *cis* conformation of the chlorides in **1**. Finally, the observation of NOE effects between the methyl groups of all three DMSO molecules in the ^1H - ^1H NOESY experiments (data not shown) confirms their *fac* arrangement.

The ^1H NMR spectrum of **2** shows a very similar pattern to that of **1**. The N1 coordination of the imidazole ring of CTZ induces a shift of 0.86 and 0.56 ppm for H2 and H4, respectively. There is a single set of signals for the two CTZ ligands and one for the four methyl groups of the DMSO molecules, suggesting a *cis* configuration for the two chlorides, *cis* for the two DMSO molecules, and *trans* for the two CTZ molecules. In this spatial arrangement two planes of symmetry and a C_2 axis make the two DMSO and the two CTZ molecules chemically and magnetically equivalent, in agreement with the NMR observations. This stereochemistry is in contrast with the *cis,cis,cis* one proposed for analogous complexes of 1,2-dimethyl imidazole³² and 1,5,6-trimethylimidazole.³³ It is reasonable to assume that the *trans* conformation is preferred for **2** in order to minimize steric repulsions between the two bulky CTZ ligands. The FT-IR spectrum shows $\nu(\text{S-O})$ at 1090 cm^{-1} and $\nu(\text{Ru-S})$ at 421 cm^{-1} , indicating a coordination of both DMSO molecules through the S atom.

Complexes **3** and **4** were prepared by reacting $\text{Na}[\text{trans-Ru}^{\text{III}}\text{Cl}_4(\text{DMSO})_2]$ with the appropriate amounts of CTZ in methanol at room temperature. Since Ru(III) is paramagnetic, the characterization of these compounds relies on elemental analysis and FT-IR spectroscopy. The results agree with the proposed structures. As seen in similar reactions,³⁴ CTZ replaces one of the DMSO molecules in complex **3** to yield a CTZ analogue of the anti-metastatic agent NAMI. The coordination of the DMSO remains through S as in the starting material, as shown by the presence of $\nu(\text{Ru-S})$ at 421 cm^{-1} and $\nu(\text{S-O})$ at 1090 cm^{-1} plus the absence of $\nu(\text{Ru-O})$. A similar analysis can be made for complex **4**. The elemental analysis confirms the presence of four chlorides and two molecules of CTZ. The *trans* geometry is proposed in view of the steric bulk of the CTZ ligands, in parallel to the antitumor agent KP1019 and related derivatives.³⁵

The set of organoruthenium-CTZ complexes **5-8** on the other hand, was synthesized by reaction of CTZ with adequate starting materials (see Scheme 2). The presence of the arene ligand provides stability, together with tunable physicochemical features through the combination with other relevant ligands in the coordination sphere of the metal atom. The molecular structures of these four new complexes were determined by X-ray diffraction and are shown in Fig. 2. Crystallographic details are contained in Table 3 (Experimental Section).

All complexes display similar “piano-stool” configurations with the *p*-cymene ligand occupying three coordination sites; the N1 atom of CTZ plus two other donor atoms from the remaining ligands complete the pseudo-octahedral coordination around the ruthenium atom. The main structural features as well as the values of relevant bond lengths and angles, listed in Table 1, are within the normal range for similar known complexes, e.g. $[\text{Ru}^{\text{II}}(\eta^6\text{-p-cymene})\text{Cl}(\text{en})][\text{PF}_6]$ ³⁶, $[\text{Ru}^{\text{II}}(\eta^6\text{-p-cymene})(\text{NO}_2)(\text{bipy})][\text{PF}_6]$ ³⁷ and $[\text{Ru}^{\text{II}}(\eta^6\text{-p-cymene})\text{Cl}(\text{acac})]$.³⁸ The structures of other (*p*-cymene) Ru^{II} (imidazole) complexes³⁹ are also comparable, including Ru-N distances ranging between 2.10 and 2.14 Å. Moreover, the Ru-N bond distances observed for **5-8** compare well with those of closely related complexes previously described by us, namely 2.03 Å in $\text{RuCl}_2(\text{BTZ})_2$ (BTZ being the bromo analogue of CTZ)^{15b} and about 2.0 Å in $[\text{Cu}(\text{CTZ})_4]\text{Cl}_2$ ^{15d}. 1D and 2D ^1H and ^{13}C NMR studies in

solution, as well as elemental analyses and FT-IR spectra (see Experimental Section) agree with the crystal structures in all cases.

In vitro antiparasitic activity and cytotoxicity

The effect of the new metal complexes **1-8** on the proliferation of *in vitro* cultures of promastigotes of *L. major* and epimastigotes of *T. cruzi*, was tested in comparison with CTZ and with Ru compounds of similar structure not containing CTZ, namely Na[*trans*-RuCl₄(DMSO)₂] (**C1**), *cis*-[RuCl₂(DMSO)₄] (**C2**) and [Ru(*p*-cymene)Cl₂]₂ (**C3**) (for details, see Experimental Section). The results are collected in Table 2 and Figure 3. The cytotoxic impact on human osteoblasts was also monitored in order to establish the potential toxicity of the compounds against normal cells (Table 2 and Figures 3C and 4). Complex **5** in particular displays a remarkably high activity against both parasites with LD₅₀ values in the sub-micromolar range against *L. major* and *T. cruzi*, respectively, that is, *110 and 58 times more active than free CTZ* in each case; also importantly, compound **5** does not display any appreciable toxicity to human osteoblasts when assayed up to 7.5 μM, which represents excellent therapeutic indexes greater than 500 and 75 for *L. major* and for *T. cruzi*, respectively (Table 2 and Fig. 4).

Other interesting observations can be made from the results in Figure 3 and Table 2. None of the reference metal compounds not containing CTZ (**C1-C3**) show any appreciable antiparasitic effect within the concentration range tested, while most Ru-CTZ complexes significantly enhance the activity of the parental drug CTZ. This evidences that it is the combination of CTZ and the metal-containing moiety in a single molecule that results in a synergistic effect that notably enhances the antiproliferative activity. The incorporation of the metal center results in critical modifications of the physicochemical properties of the drug, thus providing adequate transport properties to the target. It is also likely to open a second or alternative mechanism not available for CTZ itself, possibly selective DNA binding.

Although with the data at hand no clear structure-activity trends can be established, the pattern of efficacy follows the order **5** >> **8** > **7** > **6** in the case of the organometallic compounds for both *L. major* and *T. cruzi*. However, no specific tendencies are observed for the octahedral coordination complexes **1-4**.

In view of these results, the activity of complexes **5** and **8** was further tested against amastigotes of *L. major*, the infectious intracellular form of the parasite, which is of more therapeutic relevance. A high-content imaging assay (HCIA) was performed on *L. major* infected intraperitoneal mice macrophages, following the method described in the Experimental Section. As shown in Fig. 5, complex **5** showed significant inhibition on the proliferation of intracellular amastigotes (IC₇₀ = 29 nM). Complex **8** also displayed some effect using a higher concentration (IC₄₀ = 1 μM, data not shown); for comparison, the standard drug amphotericin B causes a similar effect only at concentrations of 5 μM (Fig. 5), while neither free CTZ, nor the metal controls **C1-C3** displayed any significant activity at concentrations as high as 1 μM.

At this point, a comparison with previously reported metal complexes is significant: RuCl₂(CTZ)₂, first described by us in 1993, is perhaps the most efficacious metal complex known against *T. cruzi in vitro*, displaying a 10-fold enhancement of the activity of free CTZ and no toxicity toward normal Vero cells;^{15a, b} unfortunately, this high *in vitro* activity did not translate to *in vivo* studies, mainly due to the low water solubility of the drug. Now we have disclosed a new family of Ru-CTZ compounds specifically designed to improve the biological properties, through a modulation of the solubility and other physicochemical features, from which **5** emerges as the most outstanding representative. As noted above,

under the conditions of our experiments, this non-toxic complex **5** enhances the activity of CTZ by a factor of 58 against *T. cruzi*, which represents almost a 6-fold increase with reference to $\text{RuCl}_2(\text{CTZ})_2$ ^{15a, b}. The molecular environments envisaged for the new complexes herein described indeed convey a higher water solubility with respect to the 4-coordinate species $\text{RuCl}_2(\text{CTZ})_2$, which is highly insoluble.^{15a, b} Nevertheless, the data for compounds **1-8** (Table 4, Experimental Section) indicate that although water solubility is an important parameter to consider in order to reach high biological activity, other factors must also be playing significant roles, as no clear correlations emerge between anti-*T. cruzi* activity and solubility alone.

A direct comparison with metal-based drugs reported for the treatment of *L. major*¹⁰⁻¹³ is not evident because of the differences in the formulations and structures of the compounds, as well as in the experimental conditions used to perform the biological tests. Nevertheless, complex **5** is, to our knowledge, the only reported metal complex displaying *low nanomolar* lethal doses ($\text{LD}_{50} = 15 \text{ nM}$) against the promastigote form and high inhibition activity on the proliferation of intracellular amastigotes ($\text{IC}_{70} = 29 \text{ nM}$) of *L. major*, the causative agent of leishmaniasis. Due to the highly promising results obtained for this novel family of Ru-CTZ compounds in our *in vitro* studies, they appear as excellent candidates for further drug development; to that end, relevant mechanistic studies and *in vivo* tests in experimental animals are currently in progress.

CONCLUSION

We have synthesized eight new complexes (**1-8**) combining clotrimazole with different ruthenium-containing fragments, and characterized them by a variety of physical methods including the crystal structures of the four organometallic Ru^{II} -CTZ compounds **5-8**. The activity of all the new compounds has been evaluated against promastigotes of *L. major* and epimastigotes of *T. cruzi*, and compared to that of CTZ, a well known anti fungal agent with moderate antiparasitic activity. In most cases, the synergy caused by the complexation of CTZ to the metal results in an enhancement of the activity, with $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})\text{Cl}_2(\text{CTZ})]$ (**5**) as the most significant case. Complex **5** increases the activity of CTZ by factors of 110 and 58 against *L. major* and *T. cruzi*, respectively, without any signs of toxicity to normal human cells. In a high-content imaging assay (HCIA) on *L. major* infected intraperitoneal mice macrophages, complex **5** showed significant inhibition on the proliferation of intracellular amastigotes ($\text{IC}_{70} = 29 \text{ nM}$), while Complex **8** displayed some effect at a higher concentration ($\text{IC}_{40} = 1 \mu\text{M}$). Therefore, these new compounds represent excellent leads for further development of possible effective treatments for leishmaniasis and Chagas' disease.

EXPERIMENTAL SECTION

Synthesis

All manipulations were performed under dry nitrogen using Schlenk techniques. Solvents (analytical grade, Aldrich) were dried and degassed prior to use by means of an Innovative Technology solvent purification unit; ruthenium trichloride hydrate (Pressure Chemicals Inc.), clotrimazole and other reagents (Aldrich) were used as received. $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})\text{Cl}_2]_2$ ⁴⁰, $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})\text{Cl}(\text{en})][\text{BF}_4]$ ⁴¹, $[\text{Ru}^{\text{II}}(\eta^6\text{-}p\text{-cymene})\text{Cl}(\text{acac})]_2$ ⁴², *cis*- $[\text{Ru}^{\text{II}}\text{Cl}_2(\text{DMSO})_4]$ ^{29a}, and $\text{Na}[\textit{trans}\text{-Ru}^{\text{III}}\text{Cl}_4(\text{DMSO})_2]$ ^{29b} were prepared according to published procedures. FT-IR spectra were measured on a ThermoFisher Nicolet 380 FT-IR spectrometer. NMR spectra were obtained using an AVANCE Bruker 400 instrument; chemical shifts are relative to residual proton or carbon signals in the deuterated solvents. The purity of the samples used for biological studies (> 95%) was determined by elemental analysis, performed by Atlantic Microlab, Norcross, Georgia.

***cis, fac*-[Ru^{II}Cl₂(DMSO)₃(CTZ)] (1)**—A solution of *cis*-[Ru^{II}Cl₂(DMSO)₄] (289 mg, 0.60 mmol) in dry methanol (10 ml) was stirred at 50 °C until complete dissolution. CTZ (205 mg, 0.60 mmol) was then added and the resulting mixture was stirred for 2 h at room temperature. The pale yellow solid that precipitated was filtered off, washed with water, ethanol and ether and dried under vacuum. 75% yield. ¹H NMR (CDCl₃) δ (ppm) 8.51 (s, H₂ from CTZ), 7.83 (s, H₄ from CTZ), 7.45 (dd, *J* = 7.8, 1.5 Hz, H₉ from CTZ), 7.36 (m, H₈, H₁₁, H₁₂, H₁₃, H₁₆, H₁₇, H₁₈ from CTZ), 7.30 (dd, *J* = 7.9, 1.6 Hz, H₇ from CTZ), 7.15 (m, H₁₀, H₁₄, H₁₅, H₁₉ from CTZ), 7.08 (dd, *J* = 7.8, 1.5 Hz, H₆ from CTZ), 6.83 (s, H₅ from CTZ), 3.50 (s, 6H from DMSO), 3.40 (s, 6H from DMSO), 3.21 (s, 6H from DMSO). IR (selected bands, cm⁻¹): 3149 (m-w), 3006 (m-w) ν(C-H from Ar), 2919 (m-w) ν(C-H), 1629 (w), 1491(m□w), 1430 (m-s), 1399 (m) ν(C=N and/or C=C from Ar), 1091 (s) ν(S-O), 421 (m) ν(Ru-S). Anal. calcd for C₂₈H₃₅N₂Cl₃S₃O₃Ru: C 43.16, H 4.70, N 3.73. Found: C 43.50, H 4.64, N 3.68.

***cis, cis, trans*-[Ru^{II}Cl₂(DMSO)₂(CTZ)₂](2)**—A solution of *cis*-[Ru^{II}Cl₂(DMSO)₄] (289 mg, 0.60 mmol) in dry methanol (10 ml) was stirred at 50 °C until complete dissolution. CTZ (410 mg, 1.20 mmol) was then added and the resulting mixture was stirred for 12 h at room temperature. The solution was filtered, concentrated to half volume and left to crystallize. Yellow-orange crystals were formed after 4 days, filtered off and washed with ether. 70% yield. ¹H NMR (CDCl₃) δ (ppm) 8.34 (s, H₂ from CTZ), 7.64 (s, H₄ from CTZ), 7.38 (dd, *J* = 7.8, 1.5 Hz, H₉ from CTZ), 7.33 (m, H₈, H₁₁, H₁₂, H₁₃, H₁₆, H₁₇, H₁₈ from CTZ), 7.20 (dd, *J* = 7.7, 1.4 Hz, H₇ from CTZ), 7.08 (m, H₁₀, H₁₄, H₁₅, H₁₉ from CTZ), 6.97 (dd, *J* = 8.0, 1.5 Hz, H₆ from CTZ), 6.77 (s, H₅ from CTZ), 3.14 (s, 12H from DMSO). IR (selected bands, cm⁻¹): 3133 (m-w), 3063 (m-w), 3016 (m-w), ν(C-H from Ar); 2919 (m-w) ν(C-H); 1629 (w), 1492(m□w), 1445 (m-s), ν(C=N and/or C=C from Ar); 1090 (s), ν(S-O); 421 (m) ν(Ru-S) Anal. calcd for C₄₈H₄₆N₄Cl₄S₂O₂Ru: C 56.04, H 4.81, N 5.33. Found: C 55.70, H 4.59, N 5.39.

Na[Ru^{III}Cl₄(DMSO)(CTZ)] (3)—A solution of Na[*trans*-Ru^{III}Cl₄(DMSO)₂] (107.4 mg, 0.25 mmol) in methanol (10 ml) was stirred at 50 °C to complete dissolution. CTZ (88 mg, 0.25 mmol) was then added and the resulting mixture was stirred for 13 h at r.t. The solvent was removed under vacuum and distilled water was added to the dried residue and stirred for 15 min. The product was extracted with 3×10 ml of dichloromethane, dried over NaSO₄ and the solvent was then evaporated to dryness to yield the final compound. 80% yield. IR (selected bands, cm⁻¹): 3145 (m-w), 3053 (m-w), 3016 (m-w), ν(C-H from Ar); 2964 (m-w), ν(C-H); 1445 (m-s), ν(C=N from Ar); 1492 (m□w), ν(C=C from Ar); 1090 (s), ν(S-O); 425 (m), ν(Ru-S). Anal. calcd for C₂₄H₂₃N₂Cl₅SONaRu•2MeOH: C 41.5, H 4.16, N 3.7. Found: C 42.2, H 3.98, N 3.91.

Na[*trans*-Ru^{III}Cl₄(CTZ)₂] (4)—A solution of Na[*trans*-Ru^{III}Cl₄(DMSO)₂] (100.0 mg, 0.24 mmol) in dry methanol (6 ml) was stirred at 50°C until complete dissolution. CTZ (245 mg, 0.71 mmol) was then added and the resulting mixture was stirred for 13 h at room temperature. The solvent was removed under vacuum and a yellow solid appeared that was redissolved in warm methanol, filtered, washed with diethyl ether and evaporated to dryness. 80% yield. IR (selected bands, cm⁻¹): 3148 (m-w), 3057 (m-w), 3028 (m-w), ν(C-H from Ar); 2921 (m-w) ν(C-H); 1445 (m-s), ν(C=N from Ar); 1490(m□w) (C=C from Ar); 1078 (s), ν(S-O). Anal. calcd for C₄₄H₃₄N₄Cl₆NaRu•2MeOH: C 54.18, H 4.16, N 5.49. Found: C 54.50, H 4.29, N 5.52.

[Ru^{II}(η⁶-*p*-cymene)Cl₂(CTZ)] (5)—[Ru^{II}(η⁶-*p*-cymene)Cl₂]₂ (201 mg, 0.3 mmol) was dissolved in acetone (30 ml). CTZ (228 mg, 0.7 mmol) was then added and the resulting solution was stirred at room temperature for 6 h. An orange precipitate starts appearing after

1 h. The solvent was reduced to 4 ml under vacuum and precipitation was completed by addition of diethyl ether (30 ml). The orange solid was filtered, washed with diethyl ether and dried under vacuum. 83 % yield. ^1H NMR (CDCl_3) δ (ppm): 7.86 (s, H_2 from CTZ), 7.47 (dd, $J = 7.8, 1.3$ Hz, H_9 from CTZ), 7.40 (dd, $J = 7.5, 1.5$ Hz, H_8 from CTZ), 7.37 (m, $H_{11}, H_{12}, H_{13}, H_{16}, H_{17}, H_{18}$ from CTZ), 7.31 (dd, $J = 7.8, 1.2$ Hz, H_7 from CTZ), 7.28 (s, H_4 from CTZ), 7.13 (m, $H_{10}, H_{14}, H_{15}, H_{19}$ from CTZ), 7.03 (dd, $J = 8.0, 1.4$ Hz, H_6 from CTZ), 6.83 (s, H_5 from CTZ), 5.32 (d, $J = 6.0$ Hz, 2H from p-cy), 5.14 (d, $J = 5.9$ Hz, 2H from p-cy), 2.87 (hept, $J = 7.0$ Hz, 1H from p-cy), 2.11 (s, 3H from pcy), 1.21 (d, $J = 6.9$ Hz, 6H from p-cy). IR (selected bands, cm^{-1}): 3144 (m-w), 3060 (m-w) $\nu(\text{C-H}$ from Ar); 2968 (m-w), $\nu(\text{C-H})$; 1530 (w), 1492(m□w), 1447 (m-s), 1432 (m) $\nu(\text{C=N}$ and/or C=C from Ar). Anal. calcd for $\text{C}_{32}\text{H}_{31}\text{N}_2\text{Cl}_3\text{Ru}$: C 59.04, H 4.80, N 4.30. Found: C 58.75, H 4.87, N 4.28. Crystals of **1** suitable for X-ray crystallography were obtained by slow evaporation of a hexane□dichloromethane solution.

[Ru^{II}(η^6 -p-cymene)(bipy)(CTZ)][BF₄]₂ (6)—[Ru^{II}(η^6 -p-cymene)Cl₂]₂ (208.5 mg, 0.341 mmol) was dissolved in acetone (30 ml). A solution of AgBF₄ (265.8 mg, 1.365 mmol) also in acetone (3 ml) was added, and the mixture was stirred protected from light at room temperature for 4 h. The orange solution was filtered to remove solid AgCl, left for 48 h at □20 °C and filtered again. 2,2'-bipyridine (106.4 mg, 0.681 mmol) was added and the reaction was left to proceed for 4 h at room temperature. CTZ (235.4 mg, 0.683 mmol) was then added and the resulting reddish-brown solution was vigorously stirred for 7 h at room temperature. The solvent was removed under vacuum, the resulting brownish solid was washed twice with hexane (2 × 30 ml), filtered and dried under vacuum. 75% yield. ^1H NMR ($\text{Me}_2\text{CO}-d_6$) δ (ppm) 9.87 (d, $J = 5.7$ Hz, 2H from bipy), 8.65 (d, $J = 8.4$ Hz, 2H from bipy), 8.40 (td, $J = 7.9, 1.4$ Hz, 2H from bipy), 7.85 (m, 2H from bipy), 7.50 (m, H_7, H_9 from CTZ), 7.38 (m, $H_8, H_{11}, H_{12}, H_{13}, H_{16}, H_{17}, H_{18}$ from CTZ), 7.31 (m, H_4 from CTZ), 7.25 (m, H_2 from CTZ), 7.16 (m, H_5 from CTZ), 6.92 (dd, $J = 8.1, 1.5$ Hz, H_6 from CTZ), 6.89 (m, $H_{10}, H_{14}, H_{15}, H_{19}$ from CTZ), 6.67 (d, $J = 6.5$ Hz, 2H from p-cy), 6.34 (d, $J = 6.5$ Hz, 2H from p-cy), 2.70 (hept, $J = 6.9$ Hz, 1H from p-cy), 2.19 (s, 3H from p-cy), 1.02 (d, $J = 6.9$ Hz, 6H from p-cy). IR (selected bands, cm^{-1}): 3128 (m-w), 3090 (m), $\nu(\text{C-H}$ from Ar); 2970 (m), 2877 (m-w), $\nu(\text{C-H})$; 1606 (m), 1495(m), 1447 (m□s), 1431 (m), $\nu(\text{C=N}$ and/or C=C from Ar). %. Anal. calcd for $\text{C}_{42}\text{H}_{39}\text{N}_4\text{ClB}_2\text{F}_8\text{Ru}\cdot 2\text{H}_2\text{O}$: C 53.33, H 4.58, N 5.92. Found: C 53.72, H 4.35, N 5.97.

A metathetical reaction of [Ru^{II}(η^6 -p-cymene)(bipy)(CTZ)][BF₄]₂ with a two-fold excess of picric acid in methanol solution at room temperature resulted in the formation of yellow-greenish crystals of [Ru^{II}(η^6 -p-cymene)(bipy)(CTZ)][C₆H₂N₃O₇]₂ (**6'**) suitable for X-ray crystallography.

[Ru^{II}(η^6 -p-cymene)(en)(CTZ)][BF₄]₂ (7)—AgBF₄ (118.4 mg, 0.608 mmol) was added to a solution of [Ru^{II}(η^6 -p-cymene)Cl(en)][BF₄] (226.7 mg, 0.543 mmol) in acetone (30 ml), and the mixture protected from light was stirred for 6 h at room temperature. The resulting solution was double filtered, evaporated to dryness and the product was extracted with a dichloromethane- acetone solvent mixture (5/1 v/v). CTZ (188.8 mg, 0.548 mmol) was then added and the resulting pale yellow solution was vigorously stirred for 4 h at room temperature. The solvent was removed under vacuum and a pale yellow solid was obtained. The product was washed with hexane, filtered and dried under vacuum.

A solution of this product in dichloromethane (30 ml) was washed with distilled water (2 × 5 ml) to remove unreacted [Ru^{II}(η^6 -p-cymene)Cl(en)][BF₄], then dried over Na₂SO₄ and evaporated to dryness to yield a pale yellow solid that was washed with diethyl ether and dried under vacuum. 40% yield. ^1H NMR ($\text{Me}_2\text{CO}-d_6$) δ (ppm) 8.368 (s, H_2 from CTZ), 7.557 (m, H_4, H_8, H_9 from CTZ), 7.444 (m, $H_7, H_{11}, H_{12}, H_{13}, H_{16}, H_{17}, H_{18}$ from CTZ),

7.326 (m, H_5 from CTZ), 7.226 (m, H_{10} , H_{14} , H_{15} , H_{19} from CTZ), 7.165 (dd, $J = 8.0$, 1.1 Hz, H_6 from CTZ), 6.078 (s, br, 2H), 5.92 (d, $J = 6.3$ Hz, 2H), 5.87 (d, $J = 6.3$ Hz, 2H), 4.307 (s, br, 2H), 2.703 (m, 2H), 2.63 (hept, $J = 7.0$ Hz, 1H), 2.319 (m, 2H), 2.239 (s, 3H), 1.21 (d, $J = 6.9$ Hz, 6H). 40%. IR (selected bands, cm^{-1}): 3320 (m), 3279 (m), $\nu(\text{N-H})$; 3172 (m-w), 3075 (m-w), $\nu(\text{C-H from Ar})$; 2967 (m-w), 2869 (m-w), $\nu(\text{C-H})$; 1599 (m), 1493(m), 1447 (m-s), $\nu(\text{C=N and/or C=C from Ar})$. Anal. calcd for $\text{C}_{34}\text{H}_{39}\text{N}_4\text{ClB}_2\text{F}_8\text{Ru}\cdot\text{Et}_2\text{O}$: C 51.40, H 5.56, N 6.31. Found: C 51.26, H 5.22, N 6.69. Crystals of **7** suitable for X-ray crystallography were obtained by slow evaporation of an acetone- d_6 solution.

[Ru^{II}(η^6 -*p*-cymene)(acac)(CTZ)][BF₄] (8**)**—[Ru^{II}(η^6 -*p*-cymene)Cl(acac)] (180 mg, 0.243 mmol) was dissolved in acetone (20 ml) and a solution of AgBF₄ (129 mg 0.26 mmol) in acetone (3 ml) was added. The mixture was stirred protected from light at room temperature for 3 h. Then, the solvent was evaporated under vacuum and dichloromethane (30 mL) was added. AgCl and the slight excess of AgBF₄ were filtered off to give a clear dark orange solution. CTZ (84.1 mg, 0.244 mmol) was then added and the reaction mixture was stirred at room temperature for 1 h. The yellow solution formed was concentrated and the product was precipitated as a yellow powder by addition of hexane (30 ml). Unreacted [Ru^{II}(η^6 -*p*-cymene)Cl(acac)] was removed by re-dissolving the product in dichloromethane and washing with distilled water (2 \times 5 ml). The dichloromethane fraction was dried over Na₂SO₄ and the solvent was evaporated to dryness to yield [Ru^{II}(η^6 -*p*-cymene)(acac)(CTZ)][BF₄] as a yellow solid. 70 % yield. ¹H NMR (CDCl₃) δ (ppm) 7.43 (m, H_8 , H_9 from CTZ), 7.36 (m, H_2 , H_{11} , H_{12} , H_{13} , H_{16} , H_{17} , H_{18} from CTZ), 7.31 (m, H_7 from CTZ), 7.24 (m, H_4 from CTZ), 7.04 (m, H_{10} , H_{14} , H_{15} , H_{19} from CTZ), 6.94 (m, H_6 , H_5 from CTZ), 5.64 (d, $J = 6.2$ Hz, 2H from pcy), 5.48 (d, $J = 6.2$ Hz, 2H from p-cy), 4.99 (s, 1H from acac), 2.71 (hept, $J = 6.9$ Hz, 1H from p-cy), 2.11 (s, 3H from p-cy), 1.77 (s, 6H from acac), 1.25 (d, $J = 6.9$ Hz, 6H from p-cy). IR (selected bands, cm^{-1}): 3178 (w), 3158 (m-w), 3060 (w), $\nu(\text{C-H from Ar})$; 2967 (m-w), 2872 (m-w), $\nu(\text{C-H})$; 1705 (m□s), $\nu(\text{C=O})$; 1566 (s), 1516 (m), 1491 (m-s), 1432 (m), $\nu(\text{C=N and/or C=C from Ar})$. Anal. calcd for $\text{C}_{37}\text{H}_{38}\text{N}_2\text{ClO}_2\text{BF}_4\text{Ru}\cdot\frac{1}{2}\text{H}_2\text{O}$: C 57.34, H 5.07, N 3.61. Found: C 57.45, H 5.08, N 3.60. Crystals of **8** suitable for X-ray crystallography were obtained by slow evaporation of a hexane□dichloromethane solution.

X-ray structure determinations

X-ray diffraction data were collected on a Bruker Apex II diffractometer. Crystal data, data collection and refinement parameters are summarized in Table 3. CIF files have been deposited with Cambridge Crystallographic Data Centre (CCDC). CCDC 861976 - 861979 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. The structures were solved using direct methods and standard difference map techniques, and were refined by full-matrix least-squares procedures on F^2 with SHELXTL (Version 6.10).^{43,44}

Trypanosomatid cultures

Trypomastigote forms of *T. cruzi* Y strain were obtained from infected BALB/c mice by cardiac puncture 4 days following the intraperitoneal infection with 10⁵ parasites. The procedure was performed minimizing the distress and pain for the animals, following the NIH guidance and animal protocol approved by UTEP's Institutional Animal Care and Use Committee (IACUC). Cell-derived trypomastigotes were initially obtained by infecting human osteoblast cells (American Type Culture Collection, Rockville, MD) as previously described.^{45,46} To maintain the trypomastigote virulence, a maximum of nine *in vitro* passages (infections) were performed. The epimastigote forms of *T. cruzi* (Y strain) were

grown in liver infusion-tryptose (LIT) medium.⁴⁷ Mammalian cell-derived trypomastigote forms of *T. cruzi* (Y strain) were obtained from infected LLC-MK₂ cell (American Type Culture Collection-ATCC, Manassas, Virginia) monolayers as described.⁴⁵ Promastigote forms of *L. major* strain Friedlin clone V1 were grown in RPMI 1640 medium (RPMI) supplemented with hemin and 10% fetal bovine serum (FBS) inactivated at 56°C for 30 min.⁴⁸

Culture of mammalian cells

Human osteoblast (ATCC # HTB-99) (American Type Culture Collection, Manassas, Virginia) cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM), supplemented with 10% inactivated FBS, along with 1% of 10,000 units/ml penicillin and 10 mg/ml streptomycin, in 0.9% sodium chloride. Cell cultures were regularly tested for *Mycoplasma* by polymerase chain reaction (PCR).⁴⁹

Evaluation of the toxicity on mammalian cell lines and anti-trypansomal activity — Alamar Blue assay

The toxicity to human osteoblasts and epimastigotes of *T. cruzi* Y strain was determined using Alamar Blue; the assay was performed as described before.⁴⁵

Luciferase assay - Leishmania major

The anti-parasitic activity of the Ru-CTZ derivatives was determined using *L. major* strain Friedlin clone V1 expressing firefly luciferase. The drugs (stock solutions in DMSO) were tested in a concentration range from 7.5 μM to 58.5 nM, and 1 μl per well was added (1% DMSO final concentration) to 96-well microplates using an Eppendorf epMotion 5070 automated pipetting system. Promastigotes (10⁶/well) were added, and parasite survival was assessed by luciferase activity with the substrate 5'-fluoroluciferin (ONE-Glo Luciferase Assay System, Promega) after 96-h incubation at 28°C, using a luminometer (Luminoskan, Thermo). The bioluminescent intensity was a direct measure of the survival of parasites. The assay was performed in triplicate in three independent experiments; lethal doses (LD₅₀) were determined for each drug.

In vitro evaluation of complexes 5 and 8 by high-content imaging assay (HCIA) - infectivity experiments

To mimic the *in vivo* infection, mice intraperitoneal macrophages were placed in a microplate and infected with amastigotes of *L. major* strain Friedlin clone V1, followed by treatment with the compounds. Previous to infecting the macrophages, *L. major* promastigotes were washed and re-suspended at a density of 1-5 × 10⁷ cells per 0.5 ml in 4% C5 mouse serum in macrophage media and incubated for 30 min at RT (without agitation). At a density of 1 × 10⁶, the macrophages were seeded in a 96-well flat-bottom microplate for 30 min prior to infection. The infection of the macrophage cells was performed for 24 h at 36°C 5% CO₂, at a ratio of 10 parasites per macrophage, in triplicate. The cells were subsequently washed twice with DMEM (with antibiotic without FBS) and incubated with the drugs. Several drug concentrations (937 nM to 29.25 nM) were assayed. The cells were fixed (4% paraformaldehyde) and stained with Alexa Fluor 488 Phalloidin (1.25:100) and DAPI (1:1000), the number of infected cells and amastigotes were determined by HCIA using a BD Pathway 855 high resolution fluorescence bioimager system (BD biosciences).⁵⁰ Filter sets appropriate for the excitation and emission spectra of Alexa Fluor 488 and DAPI (Sigma Aldrich) were selected. Images from nine contiguous image fields (3×3 montage) were acquired per well with a 20× (0.75 numerical aperture, NA) objective. For optimal segmentation and counting of parasites associated with host cells, the BDAttoVision™v1.6.2 Sub Object analysis was applied. Subsequently, the

infection index was calculated based on the mean of these triplicate values, by multiplying the percentage of infected cells by the constraint used in the HCIA assay, which was of 5 parasites per macrophage. The infection index is thus directly proportional to the % of infected cells reported in Fig. 5. The constraints employed of 5 or more parasites per macrophage were used to calculate a z-factor (statistical effect size) of 0.69, which indicates that we have an excellent and reliable assay.

Statistical Analysis

The statistical significance (p-value) of the cytotoxicity of the compounds to the promastigote and epimastigote forms of the parasites and human cells, as well as in the proliferation of the intracellular amastigotes (HCIA assay) was calculated using the General Linear Mixed Model Analysis. This analysis was used to test the linear effect of the logarithm of dose on the logit transformation of the Percent Survival. Each IC₅₀ value was obtained as the exponent of the negative ratio of the y-intercept and the slope of the fitted regression line (SAS Software, Version 9.2). To directly calculate the SE the Non-Linear Mixed Model was used. This method requires the raw data as the number of parasites that survive (r) and the total number (n) of parasites. In our HCIA and Luciferase assays we measured the fluorescence or relative luminescence, respectively, from where the percentage of survival and/or amastigotes per macrophages (not the specific number of parasites) was calculated. The graphs for display were attained using Graph Pad Prism 5 Software (GraphPad Software, Inc., La Jolla, California).

Acknowledgments

Financial support from the NIH through Grant # 5SC1GM089558-02 (to R.A. S.-D.) is gratefully acknowledged. R.A.M.'s laboratory was supported by grant # 2S06GM00812-37 from the NIH/MBRS/NIGMS/SCORE Program and Border Biomedical Research Center (BBRC) pilot research grant #5G12RR008124. The Biomolecule Analysis Core Facility (BACF), High- throughput Core Facility (HTSCF) and Statistical Consulting Laboratory (SCL) at the BBRC, UTEP, are supported by NIH/NCRR grant # 5G12RR008124. The National Science Foundation (CHE-0619638) is thanked for the acquisition of an X ray diffractometer for Columbia University. T.C. was supported by the RISE Undergraduate Research Program Grant #5R25GM069621-06. A. A. thanks the Venezuelan Academy of Sciences for a Graduate Fellowship. We thank Professor Stephen Beverley of Washington University School of Medicine for kindly providing the *L. major* strain Friedlin clone V1 expressing luciferase. We thank Ms. V. Medialdea (Brooklyn College) for assistance in the preparation of the manuscript.

ABBREVIATIONS USED

acac	acetylacetonate
bipy	bipyridine
CL	cutaneous leishmaniasis
CTZ	clotrimazole
DAPI	4',6-diamidino-2-phenylindole
en	ethylenediamine
FBS	fetal bovine serum
HCIA	high-content imaging assay
Hmtpo	5-methyl-1,2,4-triazolo[1,5-a] pyrimidin-7(4H)-one
KTZ	ketoconazole
L	Leishmania
LIT	liver infusion-tryptose

Lm	<i>Leishmania major</i>
MCL	mucocutaneous leishmaniasis
NAMI	new anti-tumour metastasis inhibitor
PCR	polymerase chain reaction
SBI	sterol biosynthesis inhibitor
T	<i>Trypanosoma</i>
VL	visceral leishmaniasis

References

1. a den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and treatment access. *Clinical Microbiology and Infection*. 2011; 17(10):1471–1477. [PubMed: 21933305] b WHO. Control of leishmaniasis. Report of a WHO expert committee. WHO Tech. Rep. Ser. 2010; 949:1–186.
2. a WHO. Control of Chagas disease. World Health Organization Technical Reports Series. 2002; 905:24–28. b Barrett MP, Burchmore RJS, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, Krishna S. The trypanosomiasis. *The Lancet*. 2003; 362(9394):1469–1480. c Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: a review. *Mem Inst Oswaldo Cruz*. 2002; 97(5):603–612. [PubMed: 12219120] d Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The Neglected Tropical Diseases of Latin America and the Caribbean: A Review of Disease Burden and Distribution and a Roadmap for Control and Elimination. *PLoS Negl Trop Dis*. 2008; 2(9):e300. [PubMed: 18820747] e Kirshhoff LV. Epidemiology of American trypanosomiasis (Chagas disease). *Adv Parasitol*. 2011; 75:1–18. [PubMed: 21820549]
3. a Bern C, Kjos S, Yabsley MJ, Montgomery SP. *Trypanosoma cruzi* and Chagas' Disease in the United States. *Clin Microbiol Rev*. 2011; 24(4):655–681. [PubMed: 21976603] b Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. *Mem Inst Oswaldo Cruz*. 2007; 102(Suppl 1):75–85. [PubMed: 17891282] c Diaz JH. Chagas disease in the United States: a cause for concern in Louisiana? *J. La. State. Med. Soc*. 2007; 159(1):21–3. 25–9. [PubMed: 17396472]
4. Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiasis and leishmaniasis. *Trends Parasitol*. 2005; 21(11):508–512. [PubMed: 16150644]
5. Selzer, PM. *Antiparasitic and Antibacterial Drug Discovery*. Wiley-VCH; Weinheim: 2009.
6. Ponte-Sucre, A.; Diaz, E.; Padron-Nieves, M. *Drug Resistance in Leishmania Parasites: Consequences, Molecular Mechanisms and Possible Treatments*. Springer; Vienna: 2012.
7. Polonio T, Efferth T. Leishmaniasis: drug resistance and natural products (review). *International Journal of Molecular Medicine*. 2008; 22(3):277–286. [PubMed: 18698485]
8. a Urbina JA. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. *Acta Tropica*. 2010; 115(1-2):55–68. [PubMed: 19900395] b Urbina JA. New Insights in Chagas' Disease Treatment. *Drugs of the Future*. 2010; 5(35):409–419. c Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. *Mem. Inst. Oswaldo Cruz*. 2009; 104(Suppl. 1):311–318. [PubMed: 19753490]
9. Urbina JA, Payares G, Molina J, Sanoja C, Liendo A, Lazard K, Piras MM, Piras R, Perez N, Wincker P, Ryley JF. Cure of Short- and Long-Term Experimental Chagas' Disease Using D0870. *Science*. 1996; 273(5277):969–971. [PubMed: 8688084]
10. a Sánchez-Delgado, RA.; Anzellotti, A.; Suárez, L. Metal complexes as chemotherapeutic agents against tropical diseases: malaria, trypanosomiasis and leishmaniasis.. In: Siegel, H.; Siegel, A., editors. *Met. Ions Biol. Syst. Vol. 41*. Marcel Dekker, Inc.; New York: 2004. p. 379-419. b Sánchez-Delgado RA, Anzellotti A. Metal Complexes as Chemotherapeutic Agents Against Tropical Diseases: Trypanosomiasis, Malaria and Leishmaniasis. *Mini Rev. Med. Chem*. 2004; 4(1):23–30. [PubMed: 14754440]

11. Navarro M, Gabbiani C, Messori L, Gambino D. Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. *Drug Discovery Today*. 2010; 15(23-24): 1070–1078. [PubMed: 20974285]
12. Fricker SP, Mosi RM, Cameron BR, Baird I, Zhu Y, Anastassov V, Cox J, Doyle PS, Hansell E, Lau G, Langille J, Olsen M, Qin L, Skerlj R, Wong RSY, Santucci Z, McKerrow JH. Metal compounds for the treatment of parasitic diseases. *J. Inorg. Biochem.* 2008; 102:1839–1845. [PubMed: 18684510]
13. O'Sullivan MC. The battle against trypanosomiasis and leishmaniasis: Metal-based and natural product inhibitors of trypanothione reductase. *Curr. Med. Chem.: Anti-Infect. Agents*. 2005; 4:355–378.
14. Alessio, E. *Bioinorganic Medicinal Chemistry*. Wiley-VCH; Weinheim: 2011.
15. a Sánchez-Delgado RA, Lizardi K, Rincon L, Urbina JA, Hubert AJ, Noels AN. Toward a novel metal-based chemotherapy against tropical diseases. 1. Enhancement of the efficacy of clotrimazole against *Trypanosoma cruzi* by complexation to ruthenium in $\text{RuCl}_2(\text{clotrimazole})_2$. *J. Med. Chem.* 1993; 36(14):2041–2043. [PubMed: 8336342] b Sánchez-Delgado RA, Navarro M, Lizardi K, Atencio R, Capparelli M, Vargas F, Urbina JA, Bouillez A, Noels AF, Masi D. Toward a novel metal based chemotherapy against tropical diseases 4. Synthesis and characterization of new metal-clotrimazole complexes and evaluation of their activity against *Trypanosoma cruzi*. *Inorg. Chim. Acta.* 1998; 275-276:528–540.c Navarro M, Lehmann T, Cisneros-Fajardo EJ, Fuentes A, Sánchez-Delgado RA, Silva P, Urbina JA. Toward a novel metal-based chemotherapy against tropical diseases.: Part 5. Synthesis and characterization of new Ru(II) and Ru(III) clotrimazole and ketoconazole complexes and evaluation of their activity against *Trypanosoma cruzi*. *Polyhedron*. 2000; 19(22-23):2319–2325.d Navarro M, Cisneros-Fajardo EJ, Lehmann T, Sánchez-Delgado RA, Atencio R, Silva P, Lira R, Urbina JA. Toward a Novel Metal-Based Chemotherapy against Tropical Diseases. 6. Synthesis and Characterization of New Copper(II) and Gold(I) Clotrimazole and Ketoconazole Complexes and Evaluation of Their Activity against *Trypanosoma cruzi*. *Inorg. Chem.* 2001; 40(27):6879–6884. [PubMed: 11754267]
16. a Martínez A, Rajapakse C, Naoulou B, Kopkalli Y, Davenport L, Sánchez-Delgado R. The mechanism of antimalarial action of the ruthenium(II)-chloroquine complex $[\text{RuCl}_2(\text{CQ})]_2$. *J. Biol. Inorg. Chem.* 2008; 13(5):703–712. [PubMed: 18305967] b Rajapakse CSK, Martínez A, Naoulou B, Jarzecki AA, Suárez L, Deregnacourt C, Sinou V, Schrével J, Musi E, Ambrosini G, Schwartz GK, Sánchez-Delgado RA. Synthesis, Characterization, and in vitro Antimalarial and Antitumor Activity of New Ruthenium(II) Complexes of Chloroquine. *Inorg. Chem.* 2009; 48(3): 1122–1131. [PubMed: 19119867] c Martínez A, Rajapakse C, Jalloh D, Dautriche C, Sánchez-Delgado RA. The antimalarial activity of Ru-chloroquine complexes against resistant *Plasmodium falciparum* is related to lipophilicity, basicity, and heme aggregation inhibition ability near water-octanol interfaces. *J. Biol. Inorg. Chem.* 2009; 14(6):863–871. [PubMed: 19343380]
17. a Otero L, Vieites M, Boiani L, Denicola A, Rigol C, Opazo L, Olea-Azar C, Maya JD, Morello A, Krauth-Siegel RL, Piro OE, Castellano E, González M, Gambino D, Cerecetto H. Novel Antitrypanosomal Agents Based on Palladium Nitrofurylthiosemicarbazone Complexes: DNA and Redox Metabolism as Potential Therapeutic Targets,. *J. Med. Chem.* 2006; 49(11):3322–3331. [PubMed: 16722651] b Vieites M, Otero L, Santos D, Olea-Azar C, Norambuena E, Aguirre G, Cerecetto H, González M, Kemmerling U, Morello A, Diego Maya J, Gambino D. Platinum-based complexes of bioactive 3-(5-nitrofuryl)acroleine thiosemicarbazones showing anti-*Trypanosoma cruzi* activity. *J. Inorg. Biochem.* 2009; 103(3):411–418. [PubMed: 19187969] c Vieites M, Otero L, Santos D, Toloza J, Figueroa R, Norambuena E, Olea-Azar C, Aguirre G, Cerecetto H, González M, Morello A, Maya JD, Garat B, Gambino D. Platinum(II) metal complexes as potential anti-*Trypanosoma cruzi* agents. *J. Inorg. Biochem.* 2008; 102(5-6):1033–1043. [PubMed: 18226837] d Demoro B, Sarniguet C, Sánchez-Delgado R, Rossi M, Liebowitz D, Caruso F, Olea-Azar C, Moreno V, Medeiros A, Comini MA, Otero L, Gambino D. New organoruthenium complexes with bioactive thiosemicarbazones as co-ligands: potential anti-trypanosomal agents. *Dalton Transactions*. 2012; 41:1534–1543. [PubMed: 22138896] e Merlino A, Otero L, Gambino D, Laura CE. 2011; 46:2639–2651.
18. Vieites M, Smircich P, Parajon-Costa B, Rodríguez J, Galaz V, Olea-Azar C, Otero L, Aguirre G, Cerecetto H, Gonzalez M, Gomez-Barrio A, Garat B, Gambino D. Potent in vitro anti-*Trypanosoma cruzi* activity of pyridine-2-thiol N-oxide metal complexes having an inhibitory

- effect on parasite-specific fumarate reductase. *J. Biol. Inorg. Chem.* 2008; 13:723–735. [PubMed: 18322709]
19. a Benitez J, Guggeri L, Tomaz I, Pessoa JC, Moreno V, Lorenzo J, Aviles FX, Garat B, Gambino D. A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: A potential anti-protozoa and anti-tumor agent. *J. Inorg. Biochem.* 2009; 103:1386–1394. [PubMed: 19695708] b Rodrigues C, Batista AA, Ellena J, Castellano EE, Benitez D, Cerecetto H, Gonzalez M, Teixeira LR, Beraldo H. Coordination of nitro-thiosemicarbazones to ruthenium(II) as a strategy for anti-trypansomal activity improvement. *European Journal of Medicinal Chemistry.* 2010; 45:2847–2853. [PubMed: 20363536]
 20. Donnici CL, Araujo MH, Oliveira HS, Moreira DRM, Pereira VRA, Souza M. d. A. Brelaz d. C. M. C. A. Leite ACL. Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: Synthesis, biological characterization and structure-activity relationships. *Bioorg. Med. Chem.* 2009; 17:5038–5043. [PubMed: 19539479]
 21. Maia, P. I. d. S.; Fernandes, A. G. d. A.; Silva, J.J.N.; Andricopulo, AD.; Lemos, SS.; Lang, ES.; Abram, U.; Deflon, VM. Dithiocarbazate complexes with the $[M(PPh_3)]^{2+}$ (M = Pd or Pt) moiety Synthesis, Characterization and anti-Tripanosoma Cruzii activity. *J. Inorg. Biochem.* 2010; 104:1276–1282. [PubMed: 20843554]
 22. Demoro B, Caruso F, Rossi M, Benitez D, Gonzalez M, Cerecetto H, Parajon-Costa B, Castiglioni J, Galizzi M, Docampo R, Otero L, Gambino D. Risedronate metal complexes potentially active against Chagas disease. *J. Inorg. Biochem.* 2010; 104:1252–1258. [PubMed: 20817265]
 23. Caballero AB, Marin C, Rodriguez-Dieguez A, Ramirez-Macias I, Barea E, Sanchez-Moreno M, Salas JM. In vitro and in vivo antiparasital activity against Trypanosoma cruzi of three novel 5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7(4H)-one-based complexes. *J. Inorg. Biochem.* 2011; 105:770–776. [PubMed: 21497152]
 24. Batista, D. d. G. J.; da, SPB.; Stivanin, L.; Lachter, DR.; Silva, RS.; Felcman, J.; Louro, SRW.; Teixeira, LR.; Soeiro, M. d. N. C. Co(II), Mn(II) and Cu(II) complexes of fluoroquinolones: Synthesis, spectroscopical studies and biological evaluation against Trypanosoma cruzi. *Polyhedron.* 2011; 30:1718–1725.
 25. Navarro M, Hernandez C, Colmenares I, Hernandez P, Fernandez M, Sierraalta A, Marchan E. Synthesis and characterization of $[Au(dppz)_2]Cl_3$. DNA interaction studies and biological activity against *Leishmania (L) mexicana*. *J. Inorg. Biochem.* 2007; 101(1):111–116. [PubMed: 17055060]
 26. Navarro M, Cisneros-Fajardo EJ, Marchan E. New silver polypyridyl complexes: synthesis, characterization, and biological activity on Leishmania mexicana. *Arzneim. Forsch.* 2006; 56:600–604. [PubMed: 17009842]
 27. Baiocco P, Ilari A, Ceci P, Orsini S, Gramiccia M, Di MT, Colotti G. Inhibitory Effect of Silver Nanoparticles on Trypanothione Reductase Activity and Leishmania infantum Proliferation. *ACS Med. Chem. Lett.* 2011; 2:230–233.
 28. Everson, d. S. L.; Teixeira, d. S. P., Jr.; Maciel, EN.; Nunes, RK.; Eger, I.; Steindel, M.; Rebelo, RA. In vitro antiprotozoal evaluation of zinc and copper complexes based on sulfonamides containing 8-aminoquinoline ligands. *Lett. Drug Des. Discovery.* 2010; 7:679–685.
 29. a Evans IP, Spencer A, Wilkinson G. Dichlorotetrakis(dimethyl sulphoxide)ruthenium(II) and its use as a source material for some new ruthenium(II) complexes. *J. Chem. Soc., Dalton Trans.* 1973; (2):204–209. b Alessio E, Balducci G, Calligaris M, Costa G, Attia WM, Mestroni G. Synthesis, molecular structure, and chemical behavior of hydrogen trans-bis(dimethyl sulfoxide)tetrachlororuthenate(III) and mer-trichlorotris(dimethyl sulfoxide)ruthenium(III): the first fully characterized chloride-dimethyl sulfoxide-ruthenium(III) complexes. *Inorg. Chem.* 1991; 30(4):609–618.
 30. a Henn M, Alessio E, Mestroni G, Calligaris M, Attia WM. Ruthenium(II)-dimethyl sulfoxide complexes with nitrogen ligands: synthesis, characterization and solution chemistry. The crystal structures of *cis, fac*- $RuCl_2(DMSO)_3(NH_3)$ and *trans, cis, cis*- $RuCl_2(DMSO)_2(NH_3)_2 \cdot H_2O$. *Inorg. Chim. Acta.* 1991; 187(1):39–50. b Alessio E, Calligaris M, Iwamoto M, Marzilli LG. Orientation and Restricted Rotation of Lopsided Aromatic Ligands. Octahedral Complexes Derived from *cis*- $RuCl_2(Me_2SO)_4$. *Inorg. Chem.* 1996; 35(9):2538–2545. [PubMed: 11666467]
 31. Sens C, Rodríguez M, Romero I, Llobet A. Synthesis, Structure, spectroscopy, Photochemical, Redox and Catalytic Properties of New Ru(II) Isomeric Complexes Containing Dimethylsulfoxide,

- Chloro and the Dinucleating bis-2-pyridylpyrazole ligands. *Inorg. Chem.* 2003; 42(6):2049–2048. [PubMed: 12639140]
32. Iwamoto M, Alessio E, Marzilli LG. Observation of an Unusual Molecular Switching Device. The Position of One 1,2-Dimethylimidazole Switched “On” or “Off” the Rotation of the Other 1,2-Dimethylimidazole in *cis,cis,cis*-Ru^{II}Cl₂(Me₂SO)₂(1,2-dimethylimidazole)₂. *Inorg. Chem.* 1996; 35(8):2384–2389. [PubMed: 11666440]
33. Marzilli LG, Iwamoto M, Alessio E, Hansen L, Calligaris M. The Rare Head-to-Head Conformation of Untethered Lopsided Ligands Discovered in Both Solution and Solid States of 1,5,6-Trimethylbenzimidazole Re(V) and Ru(II) Complexes. *JACS.* 1994; 116(2):815–816.
34. a Alessio E, Balducci G, Lutman A, Mestroni G, Calligaris M, Attia WM. Synthesis and characterization of two new classes of ruthenium(III)-sulfoxide complexes with nitrogen donor ligands (L): Na[*trans*-RuCl₄(R₂SO)(L)] and *mer, cis*-RuCl₃(R₂SO)(R₂SO)(L). The crystal structure of Na[*trans*-RuCl₄(DMSO)(NH₃)] · 2DMSO, Na[*trans*-RuCl₄(DMSO)(Im)].H₂O, Me₂CO (Im = imidazole) and *mer, cis*-RuCl₃(DMSO)(DMSO)(NH₃). *Inorg. Chim. Acta.* 1993; 203(2):205–217. b Velders AH, Bergamo A, Alessio E, Zangrando E, Haasnoot JG, Casarsa C, Cocchietto M, Zorzet S, Sava G. Synthesis and Chemical-Pharmacological Characterization of the Antimetastatic NAMI-A-Type Ru(III) Complexes (Hdmtp)[*trans*-RuCl₄(dmsO-S)(dmtP)], (Na) [*trans*-RuCl₄(dmsO-S)(dmtP)], and [*mer*-RuCl₃(H₂O)(dmsO-S)(dmtP)] (dmtP = 5,7-Dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). *J. Med. Chem.* 2004; 47(5):1110–1121. [PubMed: 14971891] c Anderson CM, Herman A, Rochon FD. Synthesis and characterization of ionic Ru(III) complexes containing dimethylsulfoxide and dinitrogen heterocyclic ligands. *Polyhedron.* 2007; 26(14):3661–3668.
35. a Cebrián-Losantos B, Reisner E, Kowol CR, Roller A, Shova S, Arion VB, Keppler BK. Synthesis and Reactivity of the Aquation Product of the Antitumor Complex *trans*-[Ru^{III}Cl₄(indazole)₂]⁻. *Inorg. Chem.* 2008; 47(14):6513–6523. [PubMed: 18553904] b Peti W, Pieper T, Sommer M, Keppler BK, Giester G. Synthesis of Tumor-Inhibiting Complex Salts Containing the Anion *trans*-Tetrachlorobis(indazole)ruthenate(III) and Crystal Structure of the Tetraphenylphosphonium Salt. *Eur. J. Inorg. Chem.* 1999; 1999(9):1551–1555. c Lipponer KG, Vogel E, Keppler BK. Synthesis, Characterization and Solution Chemistry of *trans*-Indazoliumtetrachlorobis(indazole)ruthenate(III), a New Anticancer Ruthenium Complex. IR, UV, NMR, HPLC Investigations and Antitumor Activity. Crystal Structures of *trans*-1-Methyl-Indazoliumtetrachlorobis-(1-Methylindazole)ruthenate(III) and its Hydrolysis Product *trans*-Monoaquatrichlorobis-(1-Methylindazole)-ruthenate(III). *Met.-Based Drugs.* 1996; 3(5):243–260. [PubMed: 18472901]
36. Morris RE, Aird RE, del Socorro Murdoch P, Chen H, Cummings J, Hughes ND, Parsons S, Parkin A, Boyd G, Jodrell DI, Sadler PJ. Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes. *J. Med. Chem.* 2001; 44(22):3616–3621. [PubMed: 11606126]
37. Freedman DA, Kruger S, Roosa C, Wymer C. Synthesis, Characterization, and Reactivity of [Ru(bpy)(CH₃CN)₃(NO₂)]PF₆, a Synthone for [Ru(bpy)(L₃)NO₂] Complexes. *Inorg. Chem.* 2006; 45(23):9558–9568. [PubMed: 17083258]
38. Fernández R, Melchart M, Habtemariam A, Parsons S, Sadler PJ. Use of Chelating Ligands to Tune the Reactive Site of Half-Sandwich Ruthenium(II)–Arene Anticancer Complexes. *Chemistry – A European Journal.* 2004; 10(20):5173–5179.
39. Vock CA, Scolaro C, Phillips AD, Scopelliti R, Sava G, Dyson PJ. Synthesis, Characterization, and in Vitro Evaluation of Novel Ruthenium(II)h⁶-Arene Imidazole Complexes. *J. Med. Chem.* 2006; 49(18):5552–5561. [PubMed: 16942028]
40. Bennett MA, Huang TN, Matheson TW, Smith AK. *Inorg. Synth.* 1982; 21:74–78.
41. Crabtree RH, J. Pearman A. Arene-ruthenium complexes containing nitrogen donor ligands. *J. Organomet. Chem.* 1977; 141(3):325–330.
42. Carmona D, Ferrer J, Oro LA, Apreda MC, Foces-Foces C, Cano FH, Elguero J, Jimeno ML. Synthesis, X-ray structure, and nuclear magnetic resonance (¹H and ¹³C) studies of ruthenium(II) complexes containing pyrazolyl ligands. *J. Chem. Soc., Dalton Trans.* 1990; (4):1463–1476.
43. Sheldrick, GM. SHELXTL, An Integrated System for Solving, Refining and Displaying Crystal Structures from Diffraction Data. University of Göttingen: Göttingen; Federal Republic of Germany: 1981.

44. Sheldrick GM. A short history of SHELX. *Acta Crystallogr A*. 2008; 64(Pt 1):112–122. [PubMed: 18156677]
45. Lara D, Feng Y, Bader J, Savage PB, Maldonado RA. Anti-trypanosomatid activity of ceraginsins. *J. Parasitol.* 2010; 96(3):638–642. [PubMed: 19958044]
46. Andrews NW, Colli W. Adhesion and interiorization of *Trypanosoma cruzi* in mammalian cells. *Journal of Protozoology*. 1982; 29(2):264–269. [PubMed: 7047731]
47. Camargo EP. Growth And Differentiation In *Trypanosoma Cruzi*. I. Origin Of Metacyclic Trypanosomes In Liquid Media. *Rev Inst Med Trop Sao Paulo*. 1964; 12:93–100. [PubMed: 14177814]
48. Thalhofer CJ, Graff JW, Love-Homan L, Hickerson SM, Craft N, Beverley SM, Wilson ME. In vivo imaging of transgenic Leishmania parasites in a live host. *J Vis Exp*. 2010; (41):Pii. 1980.
49. Uphoff CC, Drexler HG. Detection of mycoplasma contaminations. *Methods Mol Biol*. 2005; 290:13–23. [PubMed: 15361652]
50. Nohara LL, Lema C, Bader JO, Aguilera RJ, Almeida IC. High-content imaging for automated determination of host-cell infection rate by the intracellular parasite *Trypanosoma cruzi*. *Parasitol Int*. 2010; 59(4):565–570. [PubMed: 20688189]
51. Zhang JH, Chung TDY, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J. Biomol. Screen*. 1999; 4:67–73. [PubMed: 10838414]





Figure 1.
Clotrimazole (CTZ) with atom labeling.

**Scheme 1.**

Synthesis of complexes **1-4**: (a) 1 CTZ, MeOH, r.t.; (b) 2 CTZ, MeOH, r.t.; (c) 1 CTZ, MeOH, r.t.; (d) 3 CTZ, MeOH, r.t.





Figure 2. Molecular structures of complex **5** and the cations of complexes **6'-8** (hydrogen atoms, counterions and solvent molecules omitted for clarity).

**Scheme 2.**

Syntheses of complexes **5-8**. (a) 2 CTZ, Me₂CO, rt; (b) i. 4 AgBF₄, Me₂CO, rt, ii. 2 bipy, Me₂CO, rt, iii. 2 CTZ, rt; (c) i. AgBF₄, Me₂CO, rt, ii. CTZ, CH₂Cl₂/Me₂CO 1:1, rt; (d) i. AgBF₄, Me₂CO, rt, ii. CTZ, CH₂Cl₂, rt. For details, see Experimental Section.




Figure 3. Effect of CTZ and selected Ru-CTZ complexes on the proliferation of (A) promastigotes of *L. major*, (B) epimastigotes of *T. cruzi* and (C) human osteoblasts. Activity data for metal controls and all Ru-CTZ complexes can be found in Table 2.




Figure 4. *In vitro* antiparasitic activity of complex **5** against promastigotes of *L. major* and epimastigotes of *T. cruzi*. Effect of the effective range concentrations on human osteoblasts. CTZ-Lm, promastigotes of *L. major* treated with clotrimazole; CTZ-Tc, epimastigotes of *T. cruzi* treated with clotrimazole. Human osteoblasts were treated with the standard therapeutic concentration of benznidazol (reference drug to treat *T. cruzi* infection). See Experimental Section for details.




Figure 5. Effect of complex 5 on the proliferation of *L. major* amastigotes infecting mice intraperitoneal macrophages. The percentage of infected macrophages with five or more amastigotes was determined using a BD Pathway 855 high resolution fluorescence bioimager system. The Z-factor is 0.69 indicates that the quality of the assay is excellent. CTZ, clotrimazol; C1, C2, C3, metal controls (1.0 μ M); ◆, infected cells treated with complex 5; □, infected untreated cells; ▲, infected cells treated with 5 μ M amphotericin B.

Table 1Selected bond lengths (in Å) and angles (in deg) for complexes **5-8**.

	5	6	7	8
Ru-N1	2.098(2)	2.083(4)	2.097(2)	2.112(2)
Ru-X	2.4118(8) 2.3991(9)	2.091(3) 2.079(4)	2.156(6) 2.110(5)	2.070(1) 2.074(1)
Ar_{cen}-Ru	1.664	1.690	1.674	1.662
X-Ru-N1	84.14(6) 85.23(7)	82.0(1) 87.5(1)	87.0(2) 85.9(2)	83.83(6) 84.39(6)
X-Ru-X	88.65(3)	77.8(1)	79.0(2)	88.02(5)
Ar_{cen}-Ru-X	127.55 128.44	132.94 131.82	127.95 132.56	127.26 125.85
Ar_{cen}-Ru-N1	128.05	126.67	127.68	132.30

X = Cl, N(bipy), N(en), O(acac)

Table 2

In vitro antiparasitic activity of controls and complexes **1-8** against promastigotes of *L. major* and epimastigotes of *T. cruzi*, and cytotoxic impact on human osteoblasts (p-value < 0.0001). See Experimental Section for details.

Compound	LD ₅₀ <i>L. major</i> (μM) ¹ [Rel. Act.] ² / (T.I.) ³	LD ₅₀ <i>T. cruzi</i> (μM) ¹ (Rel. Act.) ²	IC ₅₀ Mammalian cells (μM) ⁴
	Promastigotes	Epimastigotes	Human osteoblast
C1	15.36 ± 3.68 [0.10] / (> 0.5)	> 30 [< 0.2]	> 7.5
C2	13.23 ± 4.48 [0.12] / (> 0.6)	> 30 [< 0.2]	> 7.5
C3	12.52 ± 3.34 [0.13] / (> 0.6)	> 30 [< 0.2]	> 7.5
CTZ	1.6 ± 0.5 [1.0] / (> 4.7)	5.8 ± 1.7 [1.0] / (> 1.3)	> 7.5
1	> 7.5 [< 0.2] / (< 0.5)	4.8 ± 1.9 [1.2] / (0.81)	3.9 ± 1.2
2	0.7 ± 0.3 [2.3] / (0.7)	1.1 ± 0.5 [5.3] / (0.5)	0.5 ± 0.1
3	0.3 ± 0.2 [5.3] / (2.0)	1.6 ± 0.5 [3.6] / (0.4)	0.6 ± 0.1
4	2.76 ± 0.45 [0.58] / (2.1)	5.43 ± 0.36 [1.1] / (1.1)	5.9 ± 1.0
5	0.015 ± 0.004 [110] / (> 500)	0.1 ± 0.4 [58] / (> 75)	> 7.5
6	1.4 ± 0.6 [1.1] / (> 5.4)	>> 7.5 [< 0.8] / (< 1)	> 7.5
7	1.32 ± 0.69 [1.2] / (1.7)	7.7 ± 0.1 [0.75] / (0.3)	2.2 ± 1.0
8	0.45 ± 0.15 [3.6] / (15)	2.9 ± 0.4 [2.0] / (2.3)	6.55 ± 1.69

¹LD₅₀: Median lethal dose calculated with 95% Confidence Interval; ± values are the estimated LD₅₀ interval.

²[Rel. Act.]: Realative Activity (LD₅₀ of CTZ)/(LD₅₀ of Ru-CTZ complex)

³T.I.: Therapeutic index (IC₅₀ in mammalian cells)/(LD₅₀ in parasites)

⁴IC₅₀: Median inhibitory concentration

Table 3

Crystal, intensity collection and refinement data

Lattice	[Ru ^{II} (<i>η</i> - <i>p</i> -cymene)Cl ₂ (CTZ)] (5)		[Ru ^{II} (<i>η</i> - <i>p</i> -cymene)(bipy)(CTZ)] [picrate] ₂ (6 ⁻)		[Ru ^{II} (<i>η</i> - <i>p</i> -cymene)(en)(CTZ)] [BF ₄] ₂ (7)		[Ru ^{II} (<i>η</i> - <i>p</i> -cymene)(acetate)(CTZ)] [BF ₄] ₂ (8)	
	Monoclinic	Monoclinic	Monoclinic	Triclinic	Triclinic	Monoclinic	Monoclinic	
Formula	C ₃₂ H ₃₃ Cl ₃ N ₂ Ru	C ₅₄ H _{44.31} ClN ₁₀ O _{14.64} Ru	C ₃₅ H ₄₀ B ₂ Cl ₃ F ₈ N ₄ Ru	C ₃₇ H ₃₈ BClF ₄ N ₂ O ₂ Ru	C ₃₇ H ₃₈ BClF ₄ N ₂ O ₂ Ru			
Formula weight	651.01	1204.04	898.76	766.02				
Space group	P2 ₁ /n	C2/c	P 1	P2 ₁ /n				
a / Å	10.6482(9)	24.128(6)	8.9364(10)	11.6986(7)				
b / Å	13.9927(11)	16.765(4)	11.7146(13)	18.9176(12)				
c / Å	19.5109(15)	28.339(9)	19.341(2)	15.1412(10)				
α / °	90	90	101.146(2)	90				
β / °	102.5130(10)	112.796(3)	100.106(2)	90.1030(10)				
γ / °	90	90	97.961(2)	90				
V / Å ³	2838.0(4)	10568(5)	1924.3(4)	3350.9(4)				
Z	4	8	2	4				
Temperature (K)	150(2)	150(2)	150(2)	150(2)				
Radiation (λ, Å)	0.71073	0.71073	0.71073	0.71073				
ρ (calcd.) Mg/m ³	1.524	1.513	1.551	1.518				
Absn. Coeff. / mm ⁻¹	0.860	0.427	0.687	0.607				
F(000)	1328	4931	912	1568				
Crystal size / mm	0.13 × 0.10 × 0.05	0.32 × 0.17 × 0.17	0.30 × 0.25 × 0.25	0.24 × 0.20 × 0.20				
θ range, deg.	1.81 to 31.75°	1.53 to 30.51°	1.81 to 31.00°	1.72 to 32.74°				
Reflections collected	48314	82342	32050	57659				
Indep. reflections	9604 (R _{int} = 0.0922)	16106 (R _{int} = 0.1365)	12180 (R _{int} = 0.0358)	11842 (R _{int} = 0.0400)				
R ₁ [I > 2σ(I)]	0.0496	0.0735	0.0416	0.0390				
wR ₂	0.0979	0.1866	0.0985	0.0965				
R ₁ (all data)	0.0955	0.1506	0.0525	0.0533				
wR ₂ (all data)	0.1148	0.2282	0.1032	0.1040				
GOF	1.026	1.062	1.011	1.045				

Table 4

Solubility of complexes 1-8 in water.

Compound	mg/ml	μM
1	0.24	143
2	Insoluble	Insoluble
3	0.06	90
4	Insoluble	Insoluble
5	0.05	75
6	0.98	909
7	1.63	2000
8	0.33	435